These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24326283)

  • 21. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
    Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
    Colacurci N; Fornaro F; Cobellis L; De Franciscis P; Torella M; Sepe E; Arciello A; Cacciapuoti F; Paolisso G; Manzella D
    Menopause; 2007; 14(5):879-84. PubMed ID: 17667145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis.
    Su FM; Chen YC; Cheng TT; Lin WC; Lui CC
    BMC Musculoskelet Disord; 2015 Aug; 16():209. PubMed ID: 26286481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualizing osteoporosis medications.
    Silverman S
    Menopause; 2014 Mar; 21(3):306-8. PubMed ID: 24518155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
    Li L; Roddam A; Gitlin M; Taylor A; Shepherd S; Shearer A; Jick S
    Menopause; 2012 Jan; 19(1):33-40. PubMed ID: 21926926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
    Ohta H; Hamaya E; Taketsuna M; Sowa H
    Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
    Mosca L; Grady D; Barrett-Connor E; Collins P; Wenger N; Abramson BL; Paganini-Hill A; Geiger MJ; Dowsett SA; Amewou-Atisso M; Kornitzer M
    Stroke; 2009 Jan; 40(1):147-55. PubMed ID: 18948611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmenopausal osteoporosis treatment and risk of urinary calculus development.
    Ganji MR
    Iran J Kidney Dis; 2013 May; 7(3):171-4. PubMed ID: 23689144
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
    Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
    Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.
    Tsalikis T; Zepiridis L; Zafrakas M; Dinas K; Bontis J
    Maturitas; 2005 Jun; 51(2):215-8. PubMed ID: 15917163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of postmenopausal osteoporosis with raloxifene].
    Fedelesova V; Chylova K; Dzurik
    Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
    J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoporosis treatment and prevention for postmenopausal women: current and future therapeutic options.
    Pinkerton JV; Thomas S; Dalkin AC
    Clin Obstet Gynecol; 2013 Dec; 56(4):711-21. PubMed ID: 24100598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis.
    Brandi ML
    Clin Exp Rheumatol; 2000; 18(3):309-10. PubMed ID: 10895366
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.